Credit rating assigned to Shilpa Biologicals subsidiary

New Credit FacilityCredit & Debt View source PDF Explain this filing

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.2%Reaction day

₹644.65

prior close

₹640.45

announcement price

In-mkt

timing

Nifty Microcap 250market-0.5%-0.7% vs market

Pharmaceuticals peers, median of 164sector-0.1%-1.1% vs sector

On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-0.2

15m

-0.1

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.2-0.5-0.7-0.1-1.1

Next day

-3.9-1.5-2.4-1.0-2.9

-2.9-0.9-2.0-0.5-2.4

-0.8-0.6-0.2-0.4-0.3

-5.0-1.8-3.2-1.8-3.2

-6.3-2.4-3.9-2.8-3.5

-3.7-0.7-2.9-1.8-1.8

15d

+14.4+2.4+12.0-1.6+16.0

+25.5+2.9+22.6-1.5+27.0

+45.0+1.2+43.9-1.4+46.4

+45.8+1.2+44.7-3.4+49.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

India Ratings assigned IND A+/Stable long-term and IND A1+ short-term ratings to bank loan facilities of about INR 1,250 million for Shilpa Biologicals Pvt Ltd, a material subsidiary of Shilpa Medicare. The rating action is listed as Assigned, meaning the facility has been formally rated.

Likely market impact

Investment grade rating for subsidiary debt facility supports borrowing capacity and reflects strong creditworthiness.